Yangsan Pusan National University Hospital Professor Lee Sang-yeop's Team 'Suggests New Path for Hair Loss Treatment Development'

Professor Lee Sang-yeop, Department of Family Medicine, Yangsan Pusan National University Hospital

[Asia Economy Yeongnam Reporting Headquarters Reporter Kang Woo-kwon] Professor Lee Sang-yeop's team at Yangsan Pusan National University Hospital, the Natural Products and Functional Foods Research Institute, and the stem cell research company Tstem announced on the 21st that their collaborative research verifying the effects of amniotic membrane-free stem cells for hair loss treatment was selected as an excellent paper in the journal 'Stem Cell Translational Medicine' and was first published online on the 18th.

Professor Lee Sang-yeop's team and the Natural Products and Functional Foods Research Institute conducted a 'randomized, double-blind, placebo-controlled clinical trial' by randomly dividing a total of 38 male pattern hair loss patients into two groups of 19 each to study how effective the amniotic membrane-free stem cell extract, produced using patented technology owned by Tstem, is for hair loss.

As a result, the test group showed a 16% increase in hair count at 8 weeks and a 26% increase at 16 weeks, whereas the control group experienced a 3.2% decrease at 8 weeks and only a 7.1% increase at 16 weeks. Hair thickness increased by 14% in the test group at 16 weeks, compared to only 5.5% in the control group.

Thus, when the test substance (amniotic membrane-free stem cell extract) was applied to the scalp in tonic form, after 16 weeks, hair count increased by 26% and hair thickness by 14%, confirming excellent effects. Seven participants reported side effects, but they were mild and disappeared naturally over time.

A representative from Yangsan Pusan National University Hospital stated, "This study is significant in that it presented a new path for the development of effective hair loss treatments by improving hair count and thickness without any notable side effects in the subjects through a randomized, double-blind, placebo-controlled clinical trial."

This content was produced with the assistance of AI translation services.